Archean Chemical Industries Limited has informed the Exchange about Investor Presentation
ACI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Archean Chemical Industries shared its Q4 & FY25 results and strategic roadmap. FY25 total income fell ~23% year-on-year to Rs. 10,634.5 mn, with EBITDA declining to Rs. 3,721.2 mn and profit after tax dropping ~43% to Rs. 1,849.2 mn; EPS slipped to Rs. 15 from Rs. 26.2. Q4 FY25 showed sequential improvement with revenue at Rs. 3,333.3 mn versus Rs. 2,546.6 mn in Q3. The company disclosed several strategic acquisitions: a 21.33% stake in UK-based Clas-Sic Wafer Fab (Silicon Carbide technology, total GBP 15 mn) and a 21% stake in US-based Offgrid Energy Labs (Zinc Bromide battery tech, $12 mn), both with India expansion plans. Industrial salt business returned to normalcy and bromine derivatives (CBF & PTA Synthesis) are operational. Returns ratios weakened, with RoCE falling to 12.6% from 24.1% and RoE to 10.3% from 20.5%.
Sharply weaker FY25 earnings and compressed returns ratios signal margin pressure in the core bromine/salt business, which may weigh on near-term sentiment. However, the disclosed pivot into semiconductors and energy storage through new acquisitions could open long-term growth avenues, making this a mixed signal for shareholders.